Metastatic castration-resistant prostate cancer (mCRPC) is associated with poor prognosis. Currently, treatment selection and response assessment in mCRPC still rely largely on prostate-specific ...

Clear Cell Renal cell carcinoma (ccRCC) is the most common form of kidney cancer. The VHL tumor suppressor is lost or mutated in the majority of ccRCC and hereditary mutations in VHL predispose ...

Alicia Morgans outlines anemia management in the TALAPRO-3 regimen. The trial added talazoparib to enzalutamide in HRR-mutated metastatic hormone-sensitive prostate cancer, achieving 52% rPFS risk ...

Kim Chi describes KLK2-comPAS, a trial investigating pasritamig, a bispecific IgG1 antibody that binds KLK2 and CD3. Phase one and two data in heavily pretreated patients showed radiographic ...

Talazoparib plus enzalutamide improved overall survival (OS) in the biomarker-unselected TALAPRO-2 population, but OS benefit was not statistically significant in the homologous recombination repair ...

The optimal postoperative management strategy for patients with muscle-invasive bladder cancer (MIBC) who achieve pathological complete response (pCR) after neoadjuvant therapy remains undefined. We ...

To test safety of two regimens at differing levels of radioactivity of PSMA-targeted alpha radionuclide 225Ac-J591. Patients with progressive, metastatic androgen pathway modulator resistant prostate ...

Histotripsy is a novel non-thermal, noninvasive, non-ionising ablation modality that is under investigation for the treatment of renal cell carcinoma (RCC). Histotripsy utilizes a focused ultrasound ...

Active surveillance (AS) is the preferred management for individuals with low-risk prostate cancer (PCa), but its role in intermediate-risk (IR) disease remains underreported. Given growing interest ...

Clinical Trial Protocol for LPS-Boost: Intensified [177Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease. August 17, 2026 An ...